AstraZeneca PLC's Fluenz Tetra Gets European Marketing Grant

Published: Dec 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc. (AZN: Quote,AZN.L), Friday said its nasally administered vaccine, Fluenz Tetra, got Marketing Authorisation from the European Commission. Fluenz Tetra is a four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age. Through this approval, the vaccine becomes the only intra-nasal four-strain influenza vaccine available in Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news